medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number S1

<< Back Next >>

Ann Hepatol 2006; 5 (S1)

Module V
Predictive factors for response to treatment of chronic hepatitis C

Olaechea de CB

Language: English
References: 51
Page: 24-28
PDF size: 53.90 Kb.


Text Extraction

Several studies have been carried out to identify factors that facilitate identification of chronic hepatitis C patients who are likely to respond to antiviral treatment. Predictive factors are classified into two categories:
I. predictive factors evident before treatment, and
II. predictive factors evident during treatment.


REFERENCES

  1. Butti M. Treatment de la hepatitis crónica C. Factores relacionados con la respuesta. GH continuada 2002; 1: 2.

  2. Carreño García V. Hepatitis Víricas. En Carreño I. Castillo (eds), Ibérica Barcelona: Springer-Verlag, 2001:321-71.

  3. Nacional Institute of Health Consensos Development Conference Panel Statement. Management of Hepatitis C. Hepatology 2002; 365: 1-3.

  4. Di Bisceglie AH, Hoofnagle JH. Optimal therapy of Hepatitis C. Hepatology 2002; 36: 121-7.

  5. Manns MP, et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2 plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.

  6. Hadziyannis SJ, Cheinquer H, et al. Peginterferon alfa 2a (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized double-blind multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36(Suppl.1): 3.

  7. Lindsay KL, et al. A randomized double blind trial comparing pegylated interferon alfa 2b to interferon alfa 2b as initial treatment for chronic hepatitis. Hepatology 2001; 34: 395-03.

  8. Fried NW, Shiffman ML, Reddy R, Smith C, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  9. Poynard T, et al. Meta-analysis of interferon randomized trial in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.

  10. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26(Suppl.1): S122-S127.

  11. Hayashi J, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89: 2151-6.

  12. Pawlotsky JM, et al. Factors affecting treatment responses to interferon alpha in chronic hepatitis C. J Infect Dis 1996; 174: 1-7.

  13. Ishibashi K, Kashiwagi T, Ito A, Tanaka Y, Nagata T, Tamaki J, Azuma M, Kishida Y, Yoshida A, Hikiji AY. Predictive factors for efficacy of interferon therapy in chronic hepatitis Type C. Hepatogastroenterology 1995; 42: 535-41.

  14. Saracco G, et al. Predictors of response to interferon therapy. Dig Dis Sci 1996; 41 (Suppl): S115-S120.

  15. Hayashi J, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89(12): 2151-6.

  16. Tabaru A, et al. Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a. Am J Gastroenterol 2005; 100(4): 862-7.

  17. Jiao J. Hepatitis C virus genotypes HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int 2005; 4(1): 80-3.

  18. Ferenci P. Predictors of response to therapy in Chronic Hepatitis C. Semin Liver Dis 2004; 21(Suppl.2): 25-31.

  19. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004; 53(1): 15.

  20. Shiratori et al. Predictors of the efficacy of the interferon therapy in chronic hepatitis C virus Infection. Tokyo Chiba hepatitis Research Group. Gastroenterology 1997;1/3 (2):558-66.

  21. Lee SS, Abdo AA. Predicting antiviral treatment response in chronic hepatitis C. How accurate and how soon? J Antimicrob Chemother 2003; 51: 487-91.

  22. Martinot-Pegnoux M, Boyer Pouteau M, Castelman C, Guinily N, Duchatelle V, Amperin A, Degott C, Benhamon JP, Erlinger S, Marcellin P. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998; 29(2): 214-23.

  23. Lee SS, et al. Prognostic factors of early predictivity of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 7(4): 500-6.

  24. Shiratori, et al. Predictors of the efficacy of the interferon therapy in chronic hepatitis C virus infection. Tokyo Chiba Hepatitis Research Group. Gastroenterology 1997; 1/3(2): 558-66.

  25. Muto H, et al. Types of human leukocyte antigen and decrease in HCV core antigen in serum predicting efficacy of interferon in patients with chronic hepatitis C. Analysis by a prospective study. J Gastroenterol 2004; 39(7): 674-80.

  26. Enomoto N, Sakuma I, Asahina Y et al. Comparison of fulllength sequences of interferon sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995;96:224-230.

  27. Enomoto N, Sakuma I, Asahina Y, eta al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection . N Engl J Med 1996;334:77-81.

  28. Bukh J, Miller R, Purcell R. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.

  29. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL, Perkins JD, Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996; 70: 7622-31.

  30. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of fulllength sequences of interferon sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995;96: 224-30.

  31. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.

  32. Sakuma I, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C. Differential effect of interferon on hepatitis C virus 1b quasispecies in the nonstructural protein 5A gene. J Infect Dis 1999; 180: 1001-9.

  33. Khorsi H, Castelain S, Wyseur A, et al. Mutations of hepatitis C virus 1b NS5A 2209–2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol 1997; 27: 72-7.

  34. Squadrito G, Leone F, Sartori M, et al. Mutation in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 1997; 113: 567-72.

  35. Cacciola I, Pollicino T, Squadrito G, Cerenzia G. Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.

  36. De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, Van Thiel DH. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000; 95(12): 3529-36.

  37. Pol S, Nalpas B, Bourliere M et al. Combination of ribavirin and interferon -alfa surpasses high doses of interferon- alfa alone in patients with genotype-1b- related chronic hepatitis C. Hepatology 2000;31: 1336-1344

  38. Heather M Patton, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40(3): 484-90.

  39. Bekkering FC et al Hepatitis C viral kinetics in difficult treat patients receiving high dose interferon and Ribavirin. JHepastol 2001;34;3:435-440.

  40. Brouwer J, Hansen B, Niesters H,Schalm S. Early prediction of response in interferon monotherapy and in interferon-ribavirirn combination therapy of chronic hepatitis C.HCV RNA at 4 weeks versus ALT. J Hepatol 1990;30:192-8.

  41. Alberti A., Benvegnù L. Managemente of Hepatitis C J.Hepatol 2003;38;suppl 1 : 104-118.

  42. Hu KQ Kyulo NL, Erailian E. et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States Jhepatol 2004<,40;1.147-154.

  43. Heather M Patton et al .The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol2004;40;3:484-490.

  44. Muir JA. Results of regression analysis examining effects of prognostic factors on sustained virologic response. N Engl J Med 2004;350;12:2265-2271.

  45. Layden TJ. Mathematical modeling of viral kinetica: understand and optimize therapy. Clinics in Liver Disease 2003;7;1:163-178.

  46. Heathcote EJ, Shiffman ML, Cooksley WGE et al Peg interferon alfa-2a in patients with chronic hepatitis C and cirrhosis.NEnglJMed 2000;343;23:1673-1680.

  47. Boucher E, Bourienne A, Adams P. et al. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut 1997;41:115-120.

  48. Kageyama F, Kobayashi Y ,Murohisa G, et al. Failure to respond to interferon-alpha 2ª therapy is associated with increased hepatic iron level in patients with chronic hepatitis C. Biol Trace Elem Res 1998;64:185-196.

  49. Naveau S, Balian A, Degos F. et al Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon alpha .multicenter Ger-Cyt 04 Group. J.Hepatol 1999;31:612-617.

  50. Depraetere S; Kerschaever EV, Vlierberghe HV, et al .Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. J Med Virol 2000;60:126-132.

  51. Vandelli C, Renzo F, Braun HB, et al Prediction of successful outcome in randomized controlled trial of the long term efficacy of interferon alpha treatment for chronic hepatitis C. J Med Virol 1999;58:26-34.




2020     |     www.medigraphic.com